Pharmacologic inhibition of MYCN oncoprotein is therefore of great interest in pediatric cancer; however, direct targeting of MYCN, or MYC oncoproteins in general, has not yet delivered viable therapeutics to the clinic. The gene discussed is MYCN; the disease is cancer.